Isis Spin-Off Altair Will Develop Antisense Asthma Candidate 369645
This article was originally published in The Pink Sheet Daily
Executive Summary
Isis uses “satellite” strategy to focus internal development on cardiovascular, metabolic disease candidates, including mipomersen, while expanding therapeutic indications for its antisense drugs.
You may also be interested in...
Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
Isis Lipid-Lowering Candidate Named Mipomersen; Firm Projects Smaller Loss
Firm revises net operating loss guidance downward by roughly $20 million.